Shocking nerve pain away: new device trial for diabetic neuropathy
NCT ID NCT05777317
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This study tests whether a device that sends mild electrical pulses to the spinal cord (10 kHz SCS) can reduce pain and improve nerve function in people with painful diabetic neuropathy. About 143 participants will either get standard medical care alone or the device plus standard care. The goal is to see if more people get at least 50% pain relief and show measurable nerve improvement.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- 10 kHz spinal cord stimulation (SCS) device
- What this could lead to
- If successful, this could offer a new option to significantly reduce chronic pain and improve nerve function in people with painful diabetic neuropathy.
- What could go wrong
- This is a mid-stage trial with 143 participants, so results may not apply to everyone. The device requires surgery and carries risks like infection or device malfunction.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
143 people
The number who actually took part.
- Started
-
Apr 2023
- Expected to finish
-
Jul 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
22 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Has been clinically diagnosed with diabetes, according to the American Diabetes Association guidelines, as well as painful diabetic neuropathy (PDN) of the lower limbs. * Has pain intensity (over the last 7 days) of ≥5 out of 10 cm on the Visual Analog Scale (VAS) in the lower limbs at both the Enrollment and Baseline Visits. * Has PDN symptoms that have been present ≥12 months. * Is currently taking or has tried in the past a gabapentinoid and at least one other class of analgesic with insufficient pain relief or intolerable side effects. * Has been on a stable analgesic regimen, as determined by the Investigator, for at least 30 days prior to assessing pain intensity as described in inclusion criterion #2. * Has painful diabetic sensorimotor polyneuropathy confirmed by modified Toronto Clinical Neuropathy Score (mTCNS) \>5 at enrollment. The total score must include presence of foot pain (≥1) and sensory exam findings (≥ 2). * Has hemoglobin A1c ≤10% as measured at enrollment. * Is 22 years of age or older at the time of enrollment. * Is an appropriate candidate for the surgical procedures required in this study based on the clinical judgment of the study physician. * Is willing to and capable of giving written informed consent. * Is willing and able to comply with study-related requirements and procedures and attend all scheduled visits. Exclusion Criteria: * Has a diagnosis of a lower limb mononeuropathy (e.g., causalgia, tibial or peroneal neuropathies), has had a lower limb amputation other than toes due to diabetes, or has large (≥3 cm) and/or gangrenous ulcers or active infection of the lower limbs. * Has an average pain intensity of ≥ 3 out of 10 cm on the VAS in the upper limbs due to diabetic neuropathy at enrollment. * Has a history of glycemia-related hospitalizations or emergency ward visits including ketoacidosis, hyperosmolar state, severe hypoglycemia in the previous 6 months. * Uses anticoagulants or antiplatelet agents that cannot be temporarily discontinued prior to the procedure. * Has unstable cardiovascular disease, including untreated cardiac arrhythmias, myocardial infarction within last 12 months, New York Heart Association (NYHA) Functional Class III or IV heart failure. * Is currently prescribed a daily opioid dosage \> 120 mg morphine equivalents. * Has a medical condition or diagnosis that is inconsistent with the Senza System guidelines in the Physician's Manual or as per standard clinical practice. * Has a medical condition or pain in other area(s), not intended to be treated in this study, that could interfere with study procedures, accurate pain reporting, and/or confound evaluation of study endpoints, as determined by the Investigator (such as primary headache, fibromyalgia, post-herpetic neuralgia, osteoarthritis, critical limb ischemia due to peripheral vascular disease or small vessel disease). * Has prior experience with SCS, dorsal root ganglion (DRG) stimulation, peripheral nerve field stimulation (PNfS), or peripheral nerve stimulation (PNS) for chronic intractable pain. * Has an existing drug pump and/or another active implantable device such as a pacemaker (ok to have an insulin pump or continuous glucose monitor that remains externalized). * Has a condition currently requiring or likely to require the use of diathermy or MRI that is inconsistent with Senza System guidelines in the Physician's Manual. * Has a life expectancy of less than one year. * Has a local infection at the anticipated surgical entry site or an active systemic infection. * Is pregnant or plans to become pregnant during the study (participants of child-bearing potential that are sexually active must use a reliable form of birth control). * Has had within 6 months of enrollment a significant untreated addiction to dependency producing medications, alcohol or illicit drugs. * Is concomitantly participating in another interventional clinical study. * Is involved in an injury claim for study-related chronic pain that is under current litigation. * Is a recipient of temporary Social Security Disability Insurance (SSDI) benefits due to study-related chronic pain. * Has a pending or approved worker's compensation claim for study-related chronic pain. * Has evidence of an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance with intervention and/or ability to evaluate treatment outcome, as determined by the investigator in the last 12 months. * Has a BMI \> 45 at enrollment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Painful diabetic neuropathy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina, 27157, United States
-
Touchstone Interventional Pain Center
Medford, Oregon, 97504, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Electric pulses in the spine may ease diabetic nerve pain
- Could a magnetic helmet ease diabetic nerve pain?
- Could a Low-Dose opioid blocker ease diabetic nerve pain without the risks?
- Gene therapy aimed at cutting opioid use for diabetic nerve pain – but trial never started
- New pill aims to quiet diabetic nerve pain
- New home gadget may ease diabetic foot pain